surmount-1 trial tirzepatide weight loss non-diabetic Read now: The SURPASS-EARLY found that starting #tirzepatide early in #type2diabetes led to greater improvements in blood sugar, body weight, and waist size than intensified standard care. https://bit.ly/3RWnB8m surmount-1 tirzepatide non-diabetic obesity weight

Chicago Area News New study raises concerns about malnutrition risks linked to GLP-1 weight loss drugs Illinois State Police trooper accused of sexually assaulting woman in Tinley Park Aurora hosts 50th Beep Baseball World Series Chicago dog owners report paw injuries after Hamlin Park renovations Homewood community rallies around woman who lost home in tornado: 'I just want to be able to rest' Chicago ranks among the least pet-friendly U.S

Pharmacovigilance-based drug repurposing: the search for inverse signals via openvigil identifies putative drugs against viral respiratory infections

Higher doses mean stronger appetite suppression, which means lower voluntary fluid intake, which means worse CSF dynamics

However, whether the observed differences translate into clinical outcomes remains to be studied

As treatment continues, patients may begin to notice: Smoother-looking skin Improved skin tone and texture Support for the appearance of fine lines Healthier overall skin quality Published reviews describe GHK-Cu as a copper-binding peptide associated with collagen-related skin support and improved appearance in anti-aging skincare settings